History of Present Illness:
The patient has a history of psychiatric illness. Her primary care physician from an outside facility had prescribed alprazolam (Xanax) to treat her depression. The patient reported that in 2011 she experienced pain in the right side of her back and was diagnosed with sciatica. In addition, she was diagnosed with systemic lupus erythematosus (SLE) based on a positive finding for antinuclear antibodies (ANA) and double-stranded DNA (ds-DNA). She had not consulted a rheumatologist before this visit, nor had she received any medication for these conditions. Her recent history of symptoms included photosensitivity, painful aphthous ulcers, transient rashes, joint pain, myalgias, and bruising. The results of the most recent evaluation of her SLE serology revealed negative ANA and ds-DNA results. The current medications that the patient has been prescribed at Santa Clara Valley Medical Center include lamotrigine (Lamictal), sertraline (Zoloft), and gabapentin (Neurontin).
In April 2014, the patient requested additional pain medication, such as hydrocodone/acetaminophen (Norco), during her physician visit. Consequently, as part of her pain management therapy agreement to ensure compliance, 1 she was subjected to a urine toxicology drug screening. At this time, her urine specimen, from an unwitnessed collection, tested positive for benzodiazepines using the Syva EMIT immunoassay (Siemens AG, Munich, Germany) at the cutoff of 200 ng/mL. However, results of a confirmatory test conducted via gas chromatography-mass spectrometry (GC/MS) did not identify any benzodiazepine metabolites in her urine but instead revealed the presence of a parent drug, alprazolam. Further, the same specimen tested positive for metronidazole. A visual inspection of the specimen revealed crystals on the bottom of the cup. In December 2013, this patient had tested positive for α-hydroxyalprazolam (an alprazolam metabolite; limit of detection, 10 ng/mL) and methamphetamine. At that time, she explained her positive urine-drug-test result by stating that "somebody had put something in my drink."
Family history: Her father has been diagnosed with gout, knee osteoarthritis, and enlarged heart. Her brother has been diagnosed with clinical depression.
Social history: Divorced; 3 children in the custody of their father; reported having smoked 0.5 packs of cigarettes per day for 20 years; denied any alcohol intake or illicit drug use.
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Possible Answers
1. Previously, the patient screened positive for amphetamines, which are schedule-II controlled substances, and the result was confirmed positive for methamphetamine by gas chromatography-mass spectrometry (GC/MS) in December 2013 ( Table 1) . In April 2014, a large alprazolam peak was detected via GC/ MS ( Table 1) . However, α-hydroxyalprazolam, the primary metabolite of alprazolam, was not detected in the same specimen, although the metabolite had been observed in a urine specimen collected during her previous physician visit in December 2013. Her December 2013 urine specimen had a specific gravity of 1.008, which was within the reference range (1.003 to 1.028). During a more recent visit to Santa Clara Valley Medical Center in April 2014, a dilute urine specimen from the patient had a specific gravity of 1.003. Urinalysis results included the moderate presence of amorphous phosphate crystals and a pH of 7. The gas chromatographic analysis of the same urine specimen additionally detected the presence of metronidazole.
2. Alprazolam is extensively metabolized by oxidation and conjugation. Therefore, primarily, metabolites would be expected in the urine, whereas approximately 20% of the drug is excreted as the parent compound. 2 So far 29 metabolites of alprazolam have been identified in urine. 3 Here, we test for the major metabolites α-hydroxyalprazolam and 4-hydroxyalprazolam which are formed in liver by CYP3A4. Glucuronidation of the alprazolam metabolites subsequently occurs in liver via uridine 5'-diphospho-glucuronosyltransferase (UDPglucuronosyltransferase [UGT]) before the metabolites are excreted into urine. In urine specimens collected 0 to 48 hours after administration of a single alprazolam dose (n = 1) and in urine specimens randomly collected from hospitalized patients taking alprazolam (n = 9), alprazolam concentrations were always lower than α-hydroxyalprazolam concentrations. Therefore, it is highly probable that the patient crushed and added pill fragments to the urine specimen rather than consuming the drug. www.labmedicine.com Case Studies compound. 5 The medical history of this patient did not reveal any prescription for metronidazole. The analysis of the urine identified the parent compound but not its metabolite. The antibiotic drug metronidazole might have been added to the urine or urine-like specimen as a preservative or applied to the vulva to treat an infection.
5.
To assess the quality of a urine specimen, multiple parameters should be considered. In point-of-care settings in which urine condition is observed immediately after collection, the urine temperature should be within 32°C to 38°C and can be a useful indication of adulteration. 6 Further, the specific gravity indicates the concentration of solutes in the urine, providing the hydration status of the patient. Highly diluted urine, as shown in this example, with creatinine concentration of less than 20 mg/dL can be indicative of excessive water intake to dilute or mask the presence of potentially abused drugs or of a urine-like specimen without the natural metabolic waste products. Urine osmolality, an indicator of the concentration, was 185 mOsm/kg (reference range, 50 to 1400 mOsm/kg) in this patient, suggesting the specimen was diluted, as previously shown by the specific gravity and urine creatinine results. The measured urine pH was 7.0. Because urine pH can vary widely, from 5.0 to 7.5, it is a less-sensitive marker for urine adulteration. This case further highlights the importance of confirmatory testing because the urine drug screening immunoassays lack specificity and cannot differentiate parent drugs from metabolites. If we had conducted only the screening test, we would not have identified fortification of the urine specimen with alprazolam and possible substitution of the urine specimen. One approach to prevent specimen adulteration would be to conduct witnessed collection.
Summary
In the present case, the patient had a medical history of substance abuse and repeated reports of pain and depression, which may lead to higher risk for aberrant drug-related behaviors. 
